Kaposi sarcoma · 13 regimens
Cost vs Efficacy · 4 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bevacizumab monotherapy Variant #08 | — | R 57 246 | 21d | ~6.7 mo | ~19.6 mo | ~10 | ~R 572 464 PFS proxy · indirect | 10 |
Pegylated liposomal doxorubicin monotherapy Variant #01 | — | R 15 300 | 28d | ~4.2 mo | ~13.5 mo | ~5 | ~R 76 500 PFS proxy · indirect | 24 |
Etoposide monotherapy Variant #01 | — | R 2 872 | 28d | — | — | — | — | — |
Paclitaxel monotherapy Variant #46 | — | R 2 220 | 28d | ~4.8 mo | ~12.0 mo | ~6 | ~R 13 317 PFS proxy · indirect | 85 |
ABV (Vinblastine) Variant #01 | — | R 678 | 28d | — | — | — | — | — |
Bleomycin and Vincristine (BO) Variant #01 | — | R 327 | 14d | — | — | — | — | — |
ABV (Vincristine) Variant #01 | — | R 177 | 14d | — | — | — | — | — |
Pomalidomide monotherapy N/A - secondary systemic drug | — | R 0 | 28d | ~2.7 mo | — | ~3 | ~R 0 PFS proxy · indirect | 1 |
Alitretinoin monotherapy Variant #01 Partial | — | — | 84d | — | — | — | — | — |
Interferon alfa-2b monotherapy Variant #01 Partial | — | — | 28d | ~13.2 mo | — | ~15 | — | 2 |
Interferon alfa-2a monotherapy Variant #01 Partial | — | — | 7d | ~5.4 mo | ~17.5 mo | ~24 | — | 10 |
Daunorubicin liposomal monotherapy Variant #01 Partial | — | — | 14d | — | — | — | — | — |
Placebo Partial | — | — | — | ~1.3 mo | ~7.6 mo | — | — | 11 |
13 of 13 regimens shown